Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Sales (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Sales for 4 consecutive years, with 0.37% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 214.0% to 0.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.26% through Dec 2025, up 479.0% year-over-year, with the annual reading at 1.26% for FY2025, 479.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.37% at Phathom Pharmaceuticals, up from 0.61% in the prior quarter.
  • The five-year high for Return on Sales was 18.41% in Q3 2023, with the low at 116.65% in Q4 2023.
  • Average Return on Sales over 4 years is 7.21%, with a median of 0.49% recorded in 2025.
  • The sharpest move saw Return on Sales crashed -12237bps in 2023, then skyrocketed 11414bps in 2024.
  • Over 4 years, Return on Sales stood at 5.72% in 2022, then plummeted by -2138bps to 116.65% in 2023, then surged by 98bps to 2.51% in 2024, then skyrocketed by 85bps to 0.37% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.37%, 0.61%, and 1.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.